These findings suggest that TP53 SNPs and mutations may be a potential target for RNAi therapy that selectively eliminates these modified mRNAs that have a dominant-negative effect over the wild type allele or provides survival advantage to the cancer cells. This evidence concerns the gene TP53 and cancer.